Lixisenatide (AVE0010)
EFC11319
Phase 3 small_molecule completed
Quick answer
Lixisenatide (AVE0010) for Acute Coronary Syndrome is a Phase 3 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pasteur
- Indication
- Acute Coronary Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed